Nature of Business and Organization (Details)			3 Months Ended
	Oct. 17, 2018 $ / shares	Sep. 10, 2018 item	Jun. 30, 2018 item
Number of peer reviewed			20
Number of patients with mCRPC included in study			750
Number of interim assessments in trial		2
Number of RPFS events		450
Number of efficacy analysis in OS events		490
Minimum
Percentage of patients demonstrated prostate specific antigen			40.00%
Percentage of response rate in soft tissue disease			40.00%
Percentage of Overall Survival Events Previously Planned		50.00%
Maximum
Percentage of decline from baseline			50.00%
Percentage of patients demonstrated prostate specific antigen			60.00%
Percentage of response rate in soft tissue disease			50.00%
Percentage of Overall Survival Events Previously Planned		70.00%
Novartis | Subsequent Event | Merger agreement
Cash consideration per share (in dollars per share) | $ / shares	$ 24.00